GLP-1 medications slow the rate at which the stomach empties, which means food stays in the stomach longer and fullness signals arrive sooner
Such a direct GLP-1 mechanism is supported by studies using native GLP-1 and exenatide in healthy people and patients with T2DM showing that the acute increase of HR was not preceded by a decrease in blood pressure, was not associated with changes in plasma levels of adrenaline or noradrenaline, and was independent of GLP-1 glucoregulatory effects [11, 34, 35]
Patients with pre-existing mental health conditions, including anxiety disorders, should not be automatically excluded from GLP-1 treatment, but may benefit from closer monitoring and coordinated care between their GP, diabetes specialist, and mental health professionals
sitagliptin, vildagliptin) or modest weight loss (GLP-1 analogue, e.g
They may provide significant cardiovascular benefits, as many RA and PsA patients are at increased risk for heart disease